Objective To discuss the effects of elastic band exercise on the frailty states in pre-frail elderly people.Methods This study was a randomized controlled trial. Trial registration number is ChiCTR-IOC-17012579. Seventy pre-frail elderly people were randomly divided into elastic band group (n = 35) and control group (n = 35). Elastic band exercise was applied to elastic band group, 45–60 min per time for 8 weeks by 3 days a week; no exercise was applied to the control group. The frailty states, grip strength (female/male), walking speed, and physical activity were measured by the Fried frailty phenotype at pre-intervention, 4, and 8 weeks after intervention to assess the effects of exercise.Results The elastic band group showed significant improvements in the frailty states, grip strength (female) and walking speed both after 4-week and 8-week intervention (P< 0.001), and significant improvements in grip strength (male) and physical activity after 8-week intervention (P< 0.05). Within-group analysis (pre-intervention vs. after 4-week, after 4-week vs after 8-week, pre-intervention vs after 8-week) showed significant improvements (P< 0.001) in grip strength (female/male) and walking speed in the elastic band group over time, while no significant differences in the control group (P > 0.05).Conclusion Elastic band exercise can improve frailty states in pre-frail elderly people, make them broke away from pre-frailty and restore them to non-frailty through improving the grip strength, walking speed and physical activity, and the effects after 8 weeks are better than those after 4 weeks.
Members of the Toll-like receptor (TLR) family are expressed across many cell types and play a pivotal role in driving the innate immune response. Of these, TLR7 and TLR8 are primarily expressed in immune cells including plasmacytoid dendritic cells, B cells, natural killer cells, monocytes, macrophages, and neutrophils. TLR7/8 agonists have shown promising anti-tumor activity as single agents or in combination with other immune therapies. A hallmark of TLR7/8 activation is the induction of type 1 interferons and other inflammatory cytokines. However, the mechanisms by which TLR7/8 agonism lead to robust anti-tumor immunity are not fully understood. Here, we analyze the effect of systemic TLR7/8 agonism on immune cells in the blood of patients with advanced solid tumors.
Methods
Blood samples were collected during two Phase 1 clinical studies for pharmacodynamic biomarker analysis at Baseline and 1h, 4h, or 8h postdose on Cycle 1 Day 1 (C1D1), C1D8, C3D1, C6D1, and C9D1. Levels of select cytokines in the plasma (IL-6, IL-8, IP-10, IFNα, IFNγ, and TNFα) were analyzed using a multiplex immunoassay. Transcriptional profiling of genes associated with major types of circulating immune cells and their activation states was performed.
Results
Systemic administration of EIK1001 resulted in statistically significant, time-dependent changes in cytokine proteins and transcript levels of genes in patient blood. Gene signature analysis revealed rapid induction of interferon-response genes following EIK1001 administration. EIK1001 treatment also led to rapid and transient changes in gene signatures associated with various immune cells, suggesting that systemically administered TLR7/8 agonist may impact their representation in blood. Multiple cycles of EIK1001 administration resulted in a durable increase in immune activation at later time periods, suggesting that response was maintained over repeated exposure to EIK1001. EIK1001 treatment caused a dose-proportional increase in select cytokine protein levels, which was not reflected uniformly in changes in cytokine gene expression.
Conclusions
EIK1001 treatment led to induction of genes and gene signatures associated with changes of multiple immune cell types in blood. Various chemokines and cytokines were also detectable at the protein level. These data suggest a systemic TLR7/8 agonist triggers multiple immune response pathways that may have implications for cancer immunotherapy.
Acknowledgements
The authors acknowledge review by the EIK1001 early development team as well as writing support from Rand Miller, PhD.
Trial Registration
Patient samples were acquired during the conduct of studies BDB001-101 (NCT03486301) and BDB001-102 (NCT04196530).
Ethics Approval
For both clinical studies covered by this abstract, the Principal Investigator at each site was responsible for obtaining regional Ethics Committee (EC) or Institutional Review Board (IRB) approval for the final protocol, the Sponsor approved Informed Consent Form (ICF)/assent, participant information sheet, if applicable, and any advertisements to recruit participants. All patients provided informed consent prior to taking part in each study.
BACKGROUNDAIM: To explore the clinical therapeutic effect of intraoperative internal iliac arterial chemotherapy in the course of radical surgery of cervical cancer. MATERIAL AND METHODS: To retrospectively analyse the clinical data of105patients with cervical cancer,who received a radical surgery of cervical cancer and were also administered Cisplatin(DDP)via the internal iliac artery during the operation(DDP group).A nonrandomized control group of50patients who were not administered DDP intraoperatively was used for comparison(control group).Their therapeutic effect in the near future,recurrence of postoperation and the result of follow-up(including the survival rate and recurrence rate)were analyzed and compared. RESULTS: The recurrence rate of DDP group was4.81%and5cases recurred diversion(3cases pelvic cavity diversion,2cases distant diversion)within3years` follow-up and the recurrence rate of control group was18.00%,and8cases recurred diversion(7cases pelvic cavity diversion,1cases distant diversion)within3years'follow-up.The recurrence rate of control group was higher than that of the DDP group( P =0.027).The two years'survival rate in DDP group was95.0354%and in control group was83.6237%,respectively( P =0.047).The four years'survival rate was95.0354%in DDP group and79.4833%in control group( P =0.012). CONCLUSION: Intraoperative bilateral internal iliac arterial infusion chemotherapy in the course of radical surgery of cervical cancer can lower the recurrence rate the and effectively raise the survival rate.
Objective:To explore the effect of IL-2R monoclonal antibody(Simulect)combined with other immunosuppressive drugs in function of transplant kidney.Methods:Depended upon whether or not use of Simulect 44 cases of kidney transplant were divided into 2 groups as simulect group(22 cases)and none Simulect group(22 cases).All the patients were treated by the combination of MMF+CsA(or FK506)+Pred.Results:There was no significant difference at the occurrence of delayed graft function between Simulect group(22.7%)and none Simulect group(32%)(P0.05).There was significant difference at acute rejection between 2 goups Simulect group(4.5%)and none Simulect group(27%)(P0.05).Conclusions:The use of Simulect can decrease the occurrence of acute rejection,but has no effect on delayed graft fuction,the combination of MMF+FK506+Pred have good effects on functional recovery of transplant kidney.
Background: Colon adenocarcinoma (COAD) is a highly heterogeneous disease, which is the second most common cancer in females and third in males. Collagen type I alpha 2 (COL1A2) has been documented to be involved in the carcinogenesis of multiple tumors; however, the expression and prognostic significance of COL1A2 and its underlying mechanism in COAD remains unclarified. Materials and Methods: The general profile of COL1A2, its expression pattern, and prognostic value were systematically assessed through various bioinformatics tools. The protein level of COL1A2 was verified in COAD patients using immunohistochemistry analysis. In addition, enrichment analyses were performed to explore the possible regulatory pathways of COL1A2 in COAD. Results: The mRNA and protein levels of COL1A2 were significantly increased in COAD than that in normal tissues (P < 0.05). The COL1A2 expression tended to increase along with cancer stages and nodal metastasis status in COAD, while the promoter methylation levels of COL1A2 might negatively related to its mRNA expression. Survival analysis showed that COL1A2 was a reliable predictor for distinguishing the status of disease-specific survival (DSS), overall survival (OS), and progression-free survival (PFS), and might serve as a robust independent prognostic biomarker for DSS and OS in COAD patients (P < 0.05). The enrichment analysis showed focal adhesion as the most possible regulatory pathway by COL1A2. Conclusion: Collectively, COL1A2 functioned as an independent prognostic biomarker and might be a potential therapeutic target in COAD.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)